Myrl Holida

1.5k total citations
32 papers, 996 citations indexed

About

Myrl Holida is a scholar working on Physiology, Epidemiology and Hematology. According to data from OpenAlex, Myrl Holida has authored 32 papers receiving a total of 996 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 9 papers in Epidemiology and 8 papers in Hematology. Recurrent topics in Myrl Holida's work include Lysosomal Storage Disorders Research (17 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Carbohydrate Chemistry and Synthesis (7 papers). Myrl Holida is often cited by papers focused on Lysosomal Storage Disorders Research (17 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Carbohydrate Chemistry and Synthesis (7 papers). Myrl Holida collaborates with scholars based in United States, United Kingdom and Belgium. Myrl Holida's co-authors include Carl W. White, Robert F. Wilson, Melvin L. Marcus, D. E. Laughlin, Mark L. Armstrong, Craig J. Hartley, William M. Chilian, S Rumelhart, Roger Giller and ME Trigg and has published in prestigious journals such as Circulation, Blood and PLoS ONE.

In The Last Decade

Myrl Holida

31 papers receiving 968 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Myrl Holida United States	15	396	394	281	168	165	32	996
R K Mallya United Kingdom	11	245 0.6×	101 0.3×	95 0.3×	93 0.6×	74 0.4×	19	921
Leonidas Nikolaos Diamantopoulos United States	14	175 0.4×	163 0.4×	329 1.2×	22 0.1×	32 0.2×	43	718
Bonnie Mitchell United States	14	137 0.3×	150 0.4×	86 0.3×	45 0.3×	37 0.2×	28	804
Alexandros Garyfallos Greece	20	65 0.2×	139 0.4×	104 0.4×	115 0.7×	54 0.3×	70	1.1k
Adriaan C. Moulijn Belgium	17	67 0.2×	437 1.1×	257 0.9×	80 0.5×	23 0.1×	43	904
Giusy Peluso Italy	18	79 0.2×	62 0.2×	155 0.6×	205 1.2×	159 1.0×	42	1.1k
Konstantinos Tselios Canada	20	141 0.4×	158 0.4×	55 0.2×	58 0.3×	42 0.3×	55	1.1k
Shahinaz Bedri United States	11	341 0.9×	276 0.7×	236 0.8×	11 0.1×	33 0.2×	24	1.0k
Vincent Hayes United States	17	63 0.2×	106 0.3×	377 1.3×	646 3.8×	57 0.3×	25	1.2k
Uta Erdbrüegger Germany	15	88 0.2×	177 0.4×	77 0.3×	78 0.5×	52 0.3×	20	916

Countries citing papers authored by Myrl Holida

Since Specialization

Citations

This map shows the geographic impact of Myrl Holida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myrl Holida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myrl Holida more than expected).

Fields of papers citing papers by Myrl Holida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myrl Holida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myrl Holida. The network helps show where Myrl Holida may publish in the future.

Co-authorship network of co-authors of Myrl Holida

This figure shows the co-authorship network connecting the top 25 collaborators of Myrl Holida. A scholar is included among the top collaborators of Myrl Holida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myrl Holida. Myrl Holida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laney, Dawn A., Dawn Peck, Andrea M. Atherton, et al.. (2024). Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the GLA gene across 5 years: Longitudinal data from the Fabry MOPPet Study. Genetics in Medicine Open. 2. 101891–101891. 1 indexed citations

Holida, Myrl, Aleš Linhart, Antonio Pisani, et al.. (2024). A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. Journal of Inherited Metabolic Disease. 48(1). e12795–e12795. 6 indexed citations

Hughes, Derralynn, Derlis Gonzalez, Gustavo Maegawa, et al.. (2023). Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease. Genetics in Medicine. 25(12). 100968–100968. 20 indexed citations

Bernat, John, Myrl Holida, Nicola Longo, et al.. (2023). Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study. Molecular Genetics and Metabolism. 138(2). 107027–107027. 2 indexed citations

Najafian, Behzad, Aurelio Silvestroni, Camilla Tøndel, et al.. (2022). A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. Kidney International. 102(1). 173–182. 14 indexed citations

Sariol, Alan, Laura Collins, Abby Odle, et al.. (2021). Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID ‐19 convalescent plasma donors. Transfusion. 61(7). 2099–2106. 18 indexed citations

Thomas, Christie P., et al.. (2020). Initial experience from a renal genetics clinic demonstrates a distinct role in patient management. Genetics in Medicine. 22(6). 1025–1035. 41 indexed citations

Laney, Dawn A., et al.. (2017). The Impact of Fabry Disease on Reproductive Fitness. JIMD Reports. 37. 85–97. 5 indexed citations

Warnock, David G., Derralynn Hughes, Pilar Giraldo, et al.. (2017). PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study. Molecular Genetics and Metabolism. 120(1-2). S137–S138. 2 indexed citations

10.

Holida, Myrl, et al.. (2017). Detection of three families with GLA p.A143T mutation and low α-galactosidase levels by newborn screening for Fabry disease. Molecular Genetics and Metabolism. 120(1-2). S91–S91. 1 indexed citations

11.

Hughes, Derralynn, Pilar Giraldo, Derlis Gonzalez, et al.. (2017). One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy. Molecular Genetics and Metabolism. 120(1-2). S68–S68. 1 indexed citations

12.

Göker-Alpan, Özlem, Myrl Holida, Mariusz Kłopotowski, et al.. (2015). Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. Drug Design Development and Therapy. 9. 3435–3435. 18 indexed citations

13.

Warnock, David G., Daniel G. Bichet, Myrl Holida, et al.. (2015). Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. PLoS ONE. 10(8). e0134341–e0134341. 49 indexed citations

14.

Vasef, Mohammad A., Andrew L. Gilman, Justine M. Ritchie, et al.. (2003). Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation. Bone Marrow Transplantation. 32(5). 527–533. 14 indexed citations

15.

Fleitz, Julie, S Rumelhart, Fred Goldman, et al.. (2002). Successful allogeneic hematopoietic stem cell transplantation (HSCT) for Shwachman–Diamond syndrome. Bone Marrow Transplantation. 29(1). 75–79. 43 indexed citations

16.

Trigg, Michael E., et al.. (1999). Ten‐year experience of unrelated bone marrow donor transplants in children with malignant and non‐malignant conditions. Pediatric Transplantation. 3(1). 49–59. 2 indexed citations

17.

Ballas, Zuhair K., et al.. (1998). Complete heart block in association with graft-versus-host disease. Bone Marrow Transplantation. 21(1). 85–88. 19 indexed citations

18.

Kook, Hoon, Fred Goldman, Roger Giller, et al.. (1997). Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: functional analyses of lymphocytes and correlation with immunophenotypic recovery following transplantation. Clinical and Diagnostic Laboratory Immunology. 4(1). 96–103. 17 indexed citations

19.

Goldman, Fred, Douglas Padley, Roger Giller, et al.. (1996). Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood. 88(3). 1089–1097. 6 indexed citations

20.

Alarcón, Pedro A. de, et al.. (1990). Bone Marrow Transplantation Improves Survival for Acute Lymphoblastic Leukemia in Relapse: A Preliminary Report. Journal of Pediatric Hematology/Oncology. 12(4). 468–471. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact